Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who wrote (32)	4/28/2000 5:29:00 PM
From: nigel bates	Read Replies (1) of 469

April 27 (Reuters) - British biotechnology company Oxford GlycoSciences Plc (OGS) said on Friday it was "very pleased" with the first clinical trial results for its key OGT 918 product for Gaucher disease, a rare genetic disorder of the metabolism. A paper on the trials was published in The Lancet medical journal. "Overall, the authors conclude that OGT 918 improves key clinical features of Type 1 Gaucher disease and 'could be used as monotherapy and has additional potential as a treatment combined with enzyme replacement'," the company said in a statement. "We are very pleased to have found such clear cut reference of activity of OGT 918 in our first clinical trial in Gaucher disease," it said. The trial treated 28 Gaucher disease patients with OGT 918 for a one-year period. Further trials are under way. "This key paper in The Lancet serves as a foundation for our expanding clinical programme in Gaucher disease and keeps us on track to file for marketing approval in the U.S. and Europe next year," CEO Michael Kranda said in the statement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next